Our Firm is representing numerous clients who were affected by the Stryker hip recall in this litigation, and we are looking forward to the start of Phase II mediation.
New York, NY (PRWEB) December 28, 2013
Stryker hip lawsuits (http://www.strykerhiprecallclaims.com/) filed in the wake of the 2012 Rejuvenate and ABG II Modular-Neck Hip Stem recall continue to move forward in the multicounty litigation underway in New Jersey’s Bergen County Superior Court, Bernstein Liebhard LLP reports. According to an Order dated December 16th, Phase II of early mediation is scheduled to get underway in early 2014. Among other things, the Order directs the parties to submit a list of 42 cases for the early mediation pool no later than January 10, 2013. Ultimately, 10 lawsuits will be chosen for Phase II mediation, four selected by the court, and three by each of the parties. (In Re Stryker Rejuvenate Hip Stem and the ABG II Modular Hip Stem Litigation, No. 296)
“Our Firm is representing numerous clients who were affected by the Stryker hip recall in this litigation, and we are looking forward to the start of Phase II mediation,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to offer free legal evaluations to individuals who have suffered serious complications, allegedly related to the Stryker recall for Rejuvenate and ABG II hip stems.
Stryker Hip Recall
Stryker announced the Rejuvenate and ABG II hip stem recall in July 2012, after post-market data indicated the metal components were vulnerable to a high rate of fretting and corrosion at the modular neck junction, placing recipients at risk for pain, swelling, adverse local tissue reactions, and premature failure of their hip implant.* Since then, court documents indicate that hundreds of Rejuvenate and ABG II recipients have filed lawsuits seeking compensation for their alleged injuries.
In addition to at least 600 claims pending in the New Jersey proceeding, some 462 Stryker hip lawsuits involving similar allegations are also pending in a federal multidistrict litigation underway in U.S. District Court, District of Minnesota. Like the claims filed in New Jersey, all of these lawsuits allege that the recalled components can shed dangerous amounts of metal ions into recipients’ tissue and blood stream. This has allegedly caused plaintiffs to suffer metallosis, adverse local tissue reactions, necrosis, osteolysis, and failure of the hip. (In re: Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation, MDL No. 2441)
According to the December 16th Order issued in New Jersey, Phase I of early mediation has already resulted in four Stryker hip lawsuit settlements. Ten cases were selected for the first phase, and mediation efforts will begin in four of those remaining lawsuits in January. The parties were unable to reach resolution in the two final cases chosen for Phase I of early mediation, according to the Order.
Individuals who allegedly suffered complications related to the Stryker hip recall for Rejuvenate and ABG II hip stems may be entitled to compensation for any injury-related damages they may have incurred. For more information on the Stryker hip recall, please visit Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP